NVCR News and Press, NovoCure Limited

2026-07-10 15:01:54 ET The last time I spoke about NovoCure Limited ( NVCR ), it was with a Seeking Alpha article entitled " NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching ." With respect to this article, I had given the company a Stro...

2026-07-08 16:46:50 ET More on the markets I Have Been Waiting Patiently For This Q3 Selloff Markets Trade Lower And Crude Oil Spikes Energy Supercycle, Gold Arbitrage, Small-Cap Debt Issue, And Dollar Smile 3 things to look out for on Thursday SA ana...

Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 23, to discuss the company’s financial results for the three-mo...

The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with gemcitabine and nab-paclitaxel Treatment with Optune Pax was also shown to significantly del...

2026-06-24 15:05:21 ET Investors choosing between high-growth healthcare innovators must weigh specialized diagnostics against therapeutic platforms. Choosing between HeartFlow Inc. (NASDAQ:HTFL) and NovoCure Ltd. (NASDAQ:NVCR) depends on your appetite for risk and market ad...

2026-06-22 10:59:30 ET Deciding between NovoCure (NASDAQ:NVCR) and Omeros (NASDAQ:OMER) requires a look at two different stages of medical innovation. Both companies aim to solve difficult health challenges using unique scientific approaches. NovoCure is established in t...

2026-06-21 08:35:16 ET Thesis Recently, we’ve seen NovoCure Limited ( NVCR ) announce Phase 3 topline results from the TRIDENT trial. And with disappointing data here, I now feel the hold case for NovoCure rests on a mix of durable core assets and diminished near-term ups...

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NovoCure Limited (“NovoCure” or “the Company”) (NASDAQ: NVCR ) for violations of the securities laws. The investigation fo...

2026-06-19 13:10:34 ET Deciding between a pharmaceutical giant and a niche medical innovator depends on your risk tolerance. Amgen (NASDAQ:AMGN) and NovoCure (NASDAQ:NVCR) offer vastly different paths to potential growth in 2026. Amgen is a global leader in drug manufact...

Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR) PR Newswire Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of che...